Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Pharmacyclics Reports Third Quarter 2013 Results

November 7, 2013

SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended September 30, 2013.

Financial Results for the Three and Nine Months Ended September 30, 2013

Revenue for the quarter ended September 30, 2013 was $79.1 million compared to $54.7 million for the quarter ended June 30, 2013 and $102.7 million for the quarter ended September 30, 2012. Included in revenue for the three months ended September 30, 2013 was $75 million of regulatory milestones earned by the Company under its collaboration and license agreement (the “Agreement”) with Janssen Biotech, Inc. and its affiliates (“Janssen”). As announced on August 29, 2013, the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) filing for ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Revenue for the quarters ended June 30, 2013 and September 30, 2012 consisted primarily of license and milestone revenue due to development milestones earned under the Agreement.

Revenue for the nine months ended September 30, 2013 was $136.6 million, compared to $106.7 million for the nine months ended September 30, 2012. The increase in revenue was primarily due to the $75 million of regulatory milestones earned under the Agreement upon the FDA’s acceptance for filing of the Company’s NDA for ibrutinib during the nine months ended September 30, 2013.

Non-GAAP net income reported for the quarter ended September 30, 2013 was $52.5 million, or $0.72 and $0.68 net income per basic and diluted share, respectively, compared to non-GAAP net income of $19.2 million, or $0.26 and $0.25 net income per basic and diluted share, respectively for the quarter ended June 30, 2013. Non-GAAP net income for the quarter ended September 30, 2012 was $78.8 million, or $1.13 and $1.06 net income per basic and diluted share, respectively. Non-GAAP net income reported for the nine months ended September 30, 2013 was $43.3 million, or $0.60 and $0.57 net income per basic and diluted share, respectively, compared to non-GAAP net income of $54.4 million or $0.79 and $0.74 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. See “Use of Non-GAAP Financial Measures” below for a description of our non-GAAP measures. A reconciliation between certain generally accepted accounting principles (“GAAP”) and non-GAAP measures is provided at the end of this press release.

GAAP net income for the quarter ended September 30, 2013 was $42.3 million, or $0.58 and $0.55 net income per basic and diluted share, respectively, compared to GAAP net income of $12.4 million, or $0.17 and $0.16 net income per basic and diluted share, respectively, for the quarter ended June 30, 2013. For the quarter ended September 30, 2012, GAAP net income was $75.6 million, or $1.09 and $1.02 net income per basic and diluted share, respectively. For the nine months ended September 30, 2013, GAAP net income was $2.8 million, or $0.04 net income per basic and diluted share, compared to GAAP net income of $45.9 million, or $0.66 and $0.62 net income per basic and diluted share, respectively, for the nine months ended September 30, 2012. Included in GAAP net income for the nine months ended September 30, 2013 and September 30, 2012 was stock-based compensation expense of $40.6 million and $8.5 million, respectively.

To date, the Company has earned milestone payments of $275 million under the Agreement. In addition to the $75 million, representing regulatory milestones earned under the Agreement during the three months ended September 30, 2013, the Company also earned four development milestone payments from Janssen of $50 million each, totaling $200 million. The Company may receive up to an additional $550 million ($50 million for development progress, $150 million for regulatory progress and $350 million for approval) in development, regulatory and approval milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general, Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company’s share of development costs and pre-tax commercialization losses for each calendar year.

GAAP operating expenses were $25.7 million for the quarter ended September 30, 2013, compared to $42.7 million for the quarter ended June 30, 2013 and $23.9 million for the quarter ended September 30, 2012. During the three months ended June 30, 2013, the Company exceeded the $50 million annual cap on its share of development costs under the Agreement. As such, all of the Company’s share of development and commercial costs chargeable to the collaboration during the quarter ended September 30, 2013 represents amounts incurred in excess of the annual cap (“Excess Amounts”). The Company recognizes Excess Amounts as a reduction to operating expenses. For the quarter ended September 30, 2013, the Company recognized $45.5 million of Excess Amounts as a reduction to operating expenses. There were no Excess Amounts recognized for the quarter ended September 30, 2012. Of the Excess Amounts recognized for the quarter ended September 30, 2013, $34.1 million was recorded as a reduction to research and development expenses and $11.4 million was recorded as a reduction to general and administrative expenses.

GAAP operating expenses were $124.1 million for the nine months ended September 30, 2013, compared to $63.4 million for the nine months ended September 30, 2012. During the nine months ended September 30, 2013, the Company recognized $65.9 million of Excess Amounts as a reduction to operating expenses. There were no Excess Amounts recognized for the nine months ended September 30, 2012. Of the Excess Amounts recognized for the nine months ended September 30, 2013, $51.5 million was recorded as a reduction to research and development expenses and $14.4 million was recorded as a reduction to general and administrative expenses.

Under the Agreement, Janssen will fund maximum Excess Amounts of $200 million and $25 million of interest thereon. To date, the Company has recorded Excess Amounts amounting to $84.0 million. The Company recognizes Excess Amounts as a reduction to operating expenses as the Company’s repayment of Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only from the Company’s share of pre-tax profits (if any) after the third profitable calendar quarter for the product.

As of September 30, 2013, the Company had cash, cash equivalents and marketable securities of $560.1 million, compared with $317.1 million as of December 31, 2012.

As of September 30, 2013, cash, cash equivalents, marketable securities and accounts receivable from Janssen totaled approximately $612.3 million. The Company now expects to end calendar year 2013 in excess of $600 million in cash, cash equivalents, marketable securities and receivables due from Janssen.

With the progress and achievements to date, the Company expects to be profitable on a GAAP basis for the quarter and year ending December 31, 2013.

“Team Pharmacyclics has consistently improved enrollment and data submission timelines for our CLL and MCL studies over the past years. Often the clinical accomplishments are ahead of our internal expectations,” said Bob Duggan, CEO and Chairman of the Board.”Most recently we achieved an important milestone with ibrutinib’s drug application now being submitted to the European authorities. Together with Janssen, our partner, we are working towards a broad clinical advancement of ibrutinib and have now focused in on making the product commercially available in all major markets around the world. Over the next several quarters, we are anticipating additional clinical and regulatory progress. We are on our way to becoming a true ally for patients and physicians, addressing serious, unmet medical health care needs for patients.”

Regulatory and Clinical Update

To date, over 2300 patients have been treated in company sponsored trials, over 800 principal investigators have been involved in the conduct of our clinical trials in 37 countries around the globe. Clinical trials are active in all regions including US, Europe, Asia Pacific, Asia, and Latin America. Currently there are eight Phase III clinical trials conducted with ibrutinib and a total of 35 trials are currently registered on www.clinicaltrials.gov.

On October 30, Janssen announced it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of ibrutinib in the treatment of adult patients with R/R CLL/SLL or R/R MCL, two forms of blood cancer. The EMA filings follow the New Drug Application submission of ibrutinib to the U.S. Food and Drug Administration which was accepted by the agency on August 27, 2013, for its use in the treatment of patients with R/R CLL/SLL or R/R MCL.

Oral Presentations at ASH (December 7-10) for ibrutinib

Ten Oral Presentations and eleven Poster Presentations for ibrutinib have been accepted at the American Society of Hematology (ASH) Annual Meeting in New Orleans, LA (December 7-10, 2013). These abstracts were published today on the ASH website at www.hematology.org at approximately 9:00 a.m. ET. Clinical presentations scheduled during the meeting in December will provide further updates to these abstracts regarding the efficacy and safety of ibrutinib, particularly in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom’s macroglobulinemia and non-Hodgkin lymphoma.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Oral Presentations:

Title: Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk Chronic Lymphocytic Leukemia (CLL): new, updated results of a Phase II trial in 40 patients

Session: 642. CLL: Therapy, excluding Transplantation: Clinical Trials of B Cell Receptor Signaling Inhibitors

Date: Monday, December 9, 2013

Presentation Time: 5:00 PM

Location: Ernest N. Morial Convention Center, 295-296

Presenter: Burger

Title: Ibrutinib in Combination with Bendamustine and Rituximab is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase 1b Study

Session: CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials

Date: Monday, December 9, 2013 Session Time: 2:45 PM – 4:15 PM

Presentation Time: 3:15 PM

Location: Ernest N. Morial Convention Center, 220-222

Presenter: Brown

Title: Clonal evolution in patients with chronic lymphocytic leukemia developing resistance to BTK inhibition

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of CLL and Genomic Alterations in CLL Pathogenesis

Date: Tuesday, December 10, 2013

Presentation Time: 7:45 AM

Location: Ernest N. Morial Convention Center, 288-290

Presenter: Burger

Title: Single agent Ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p

Session: 642. CLL: Therapy, excluding Transplantation: Clinical Trials of B Cell Receptor Signaling Inhibitors

Date: Monday, December 9, 2013

Presentation Time: 4:30 PM

Location: Ernest N. Morial Convention Center, 295-296

Presenter: Farooqui

Title: Ibrutinib inhibits B-cell adhesion and causes an efflux of chronic lymphocytic leukemia cells from the tissue microenvironment into the blood leading to a transient treatment-induced lymphocytosis

Session: 642. CLL: Therapy, excluding Transplantation

Date: Monday, December 9, 2013

Presentation Time: 4:45 PM

Presenter: Mustafa

Title: Effective inhibition of tumor microenvironment interactions in CLL patients treated with the BTK inhibitor ibrutinib result in sustained inhibition of tumor proliferation and survival pathways

Session: 641. CLL: Biology and Pathophysiology, excluding Therapy

Date: Sunday, December 8, 2013

Presentation Time: 5:45 PM

Location: Ernest N. Morial Convention Center, 288-290

Presenter: Herman

Title: In-vivo effects of ibrutinib on the migration of chronic lymphocytic leukemia cells differ between patients and reduce the ability of the bone marrow microenvironment to attract the tumor cells

Session: 604. Molecular Pharmacology, Drug Resistance

Date: Monday, December 9, 2013

Presentation Time: 5:15 PM

Location: Ernest N. Morial Convention Center, 275-277

Presenter: Herman

Non Hodgkin Lymphoma Oral Presentations:

Title: Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin’s lymphoma

Session: 624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas

Date: Tuesday, December 10, 2013

Presentation Time: 8:45 AM

Location: Ernest N. Morial Convention Center, La Nouvelle Ballroom AB

Presenter: Younes

Waldenstrom’s Macroglobulinemia Oral Presentations:

Title: A Prospective Multicenter Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Session: 624.Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Novel Therapies for Indolent Lymphomas

Date: Monday, December 9, 2013

Presentation Time: 8:00 AM

Location: Ernest N. Morial Convention Center, La Nouvelle Ballroom AB

Presenter: Treon

Other Ibrutinib Oral Presentations:

Title: Ibrutinib (PCI-32765) antagonizes Rituximab-dependent NK-cell mediated cytotoxicity

Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Modulating the Immune System in Lymphoma

Date: Monday, December 9, 2013

Presentation Time: 10:30 AM

Location: Ernest N. Morial Convention Center, 220-222

Presenter: Kohrt

Selected Clinical Trials Initiated with ibrutinib Over the Last 21 Months

CLL/SLL

    --  RESONATE(TM) (PCYC-1112) Phase III study of ibrutinib versus ofatumumab
        in patients with R/R CLL/SLL started in the second quarter of 2012. This
        is a randomized, multi-center, open-label Phase III trial of ibrutinib
        as a monotherapy. The enrollment of 391 patients was completed more than
        two quarters ahead of schedule in April 2013. The primary endpoint of
        this study is to demonstrate a statistically significant improvement in
        progression-free survival (PFS) when compared to ofatumumab. A
        pre-defined number of progression events will trigger an interim
        analysis. Pharmacyclics expects a read out from the interim analysis
        during the first quarter of 2014. If the treatment effect of ibrutinib
        in comparison to ofatumumab is deemed statistically favorable by an
        independent review committee, a discussion with the FDA and other health
        authorities for a potential early filing may take place.
    --  RESONATE(TM)-17 (PCYC-1117): Phase II study of ibrutinib in a
        single-arm, open-label, multi-center trial using ibrutinib as a
        monotherapy in patients who have deletion 17p and who did not respond to
        or relapsed after at least one prior treatment (a high unmet need
        population) started in the first quarter of 2013. The primary endpoint
        of the study is overall response rate (ORR). This global study completed
        its enrollment of 145 patients more than two quarters ahead of schedule.
    --  RESONATE(TM)-2 (PCYC-1115): Phase III study of ibrutinib versus
        chlorambucil in frontline newly diagnosed elderly CLL/SLL patients
        started in the first quarter of 2013. This is a randomized, multicenter,
        open-label trial of ibrutinib as a monotherapy versus chlorambucil in
        patients 65 years or older with treatment naïve CLL/SLL. The study
        design was agreed upon with the FDA under a Special Protocol Assessment
        (SPA). The study is designed to demonstrate superiority of ibrutinib
        with the primary endpoint of PFS when compared to chlorambucil.
        Pharmacyclics plans to enroll 272 patients worldwide and enrollment is
        now targeted to be completed by the second quarter of 2014, one quarter
        earlier than previously announced.
    --  HELIOS (CLL3001): Phase III study of ibrutinib in combination with
        bendamustine and rituximab in patients with R/R CLL/SLL started
        enrolling patients in the third quarter of 2012. This is a randomized,
        multi-center, double-blinded, placebo-controlled trial of ibrutinib in
        combination with bendamustine and rituximab versus placebo in
        combination with bendamustine and rituximab in R/R CLL/SLL patients who
        received at least one line of prior systemic therapy. The primary
        endpoint of the study is to demonstrate a clinically significant
        improvement in PFS when compared to bendamustine and rituximab. The
        enrollment target of this global study is 580 patients.

MCL

    --  SPARK (MCL2001): Phase II study of ibrutinib in patients with R/R MCL
        who progressed after bortezomib therapy started in the third quarter of
        2012. This is a single-arm, multi-center trial of ibrutinib as a
        monotherapy in R/R MCL patients who received at least one prior
        rituximab-containing chemotherapy regimen and who progressed after
        bortezomib therapy. The primary endpoint of the study is ORR. Enrollment
        in MCL2001 was completed in April of 2013 with 120 patients enrolled.
    --  RAY (MCL3001): Phase III study of ibrutinib versus temsirolimus in R/R
        MCL patients started in the fourth quarter of 2012. This is a
        randomized, multi-center, open-label trial of ibrutinib as a monotherapy
        versus temsirolimus in R/R MCL patients who received at least one prior
        rituximab-containing chemotherapy regimen. The primary endpoint of the
        study is PFS. The enrollment target of this global study is 280
        patients.
    --  SHINE (MCL3002): Phase III study of ibrutinib in combination with
        bendamustine and rituximab in elderly patients with newly diagnosed MCL
        started in the second quarter of 2013. This is a randomized,
        multi-center, double-blinded, placebo-controlled trial of ibrutinib plus
        bendamustine and rituximab versus placebo plus bendamustine and
        rituximab in patients 65 years or older with newly diagnosed MCL. The
        primary endpoint of the study is PFS. The enrollment target of this
        global study is 520 patients.
    --  MCL4001: A multicenter, open label Expanded Access Program for ibrutinib
        as a monotherapy in relapsed/refractory (R/R) MCL patients was initiated
        in the US in the second quarter of 2013. EAPs are clinical studies
        allowed under certain circumstances by the FDA. They are designed to
        provide a mechanism for access to an investigational drug to treat
        patients with a serious or immediately life-threatening diseases or
        conditions until the time of an anticipated U.S. marketing approval.
        Further information about this program can be found on
        www.clinicaltrials.gov.

DLBCL

    --  PCYC-1106: Phase II study of ibrutinib in patients with relapsed or
        refractory diffuse large B-cell lymphoma (DLBCL). This multicenter,
        open-label trial designed to assess the activity of ibrutinib in two
        genetically distinct subtypes of DLBCL, the activated B-cell (ABC)
        subtype and the germinal center B-cell (GCB) subtype started in the
        second quarter of 2011. This trial is active in several US sites and
        Pharmacyclics has enrolled 70 patients with updated results most
        recently published at the Annual Meeting of the European Hematology
        Association in June of 2013. In July of 2013 a new cohort with ibrutinib
        dosed at 840mg in patients with non-GCB subtype DLBCL was initiated.
        Pharmacyclics is currently enrolling patients in this new cohort.
    --  DBL1002: Phase Ib dose escalating study of ibrutinib in combination with
        R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin
        Lymphoma (DLBCL, MCL, FL) started in the second quarter of 2012. The
        purpose of this study is to identify a safe and tolerable dose of
        ibrutinib in combination with R-CHOP. This global, multi-center study
        has been fully accrued with 17 patients and an update on the dose
        escalating phase of this study was provided at ASCO 2013. With a
        recommended Phase II dose established, an additional 15 patients with
        newly diagnosed DLBCL enrolled in the study. DBL1002 is currently in the
        follow up phase.
    --  DBL3001: Phase III study of ibrutinib in combination with R-CHOP
        (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
        in patients with newly diagnosed the non-GCB subtype of DLBCL started in
        the third quarter of 2013. This is a randomized, multi-center,
        double-blinded, controlled trial of ibrutinib plus R-CHOP versus R-CHOP
        in patients with newly diagnosed non-GCB subtype DLBCL. The primary
        endpoint of the study is to demonstrate a clinically significant
        improvement in event-free survival when compared to R-CHOP. The
        enrollment target of this global study is 800 patients.

FL

    --  FLR2002: Phase II study of ibrutinib in patients with R/R follicular
        lymphoma (FL) started in the second quarter of 2013. This is a
        multi-center, global trial of ibrutinib in patients with
        chemoimmunotherapy-resistant FL, whose disease has relapsed from at
        least 2 prior lines of therapy, including at least 1 rituximab
        combination chemotherapy regimen. The primary endpoint of this study is
        overall response rate. The enrollment target of this global study is 110
        patients.
    --  FLR3001: Phase III study of ibrutinib in patients with R/R indolent
        Non-Hodgkin's Lymphoma (iNHL) was initiated in the third quarter of
        2013. This is a multi-center, global trial of ibrutinib in patients with
        chemoimmunotherapy-experienced FL and marginal zone lymphoma (MZL),
        whose disease has relapsed from at least 1 prior therapy. The primary
        endpoint of this study is progression free survival. The enrollment
        target of this global study is 400 patients.

WM

    --  Phase II study of ibrutinib in patients with R/R Waldenstrom's
        Macroglobulinemia (WM) was started in the second quarter of 2012. This
        is a multicenter, open label study with a primary endpoint of ORR and is
        currently exploring ibrutinib administration at 420 mg in patients with
        WM who have failed at least 1 prior therapy. The study will also assess
        the safety and tolerability of ibrutinib as well as progression-free
        survival. This study is sponsored by the Dana-Farber Cancer Institute
        and completed enrollment of 63 patients.

MM

    --  PCYC-1111: Phase II study of ibrutinib in patients with R/R multiple
        myeloma (MM) started in the first quarter of 2012. This is a Phase II,
        multi-center, open-label trial designed to assess the safety and
        efficacy of ibrutinib single agent and in combination with dexamethasone
        in patients with R/R MM. This study is conducted by Pharmacyclics and is
        currently exploring ibrutinib administration at 560 mg in combination
        with dexamethasone and 840 mg in combination with dexamethasone and 840
        mg as a single agent. Enrollment in stage I of dosing cohorts 1-4 is
        complete with a total of 67 patients enrolled. At this time, an
        expansion of cohorts 1 and 2 is not planned due to the fact that the
        protocol-defined response rate was not achieved. Dosing of the enrolled
        patients in cohorts 3 and 4 is continuing.
    --  PCYC-1119: Phase I/IIb study of ibrutinib in combination with
        carlfizomib in patients with R/R MM was registered in the third quarter
        of 2013. The Phase I portion of this study is a dose escalation study
        designed to the safety and recommended Phase IIb dose of ibrutinib and
        carlfizomib. The Phase IIb portion will be a randomized, double-blind,
        placebo controlled study to evaluate the efficacy of ibrutinib and
        carlfizomib versus carlfizomib and placebo. The primary endpoint of the
        Phase IIb portion of the study is progression-free survival.
        Pharmacyclics plans to enroll up to 176 patients.

Conference Call

The Company will hold a conference call today at 4:30 p.m. ET. To participate in the conference call, please dial 1-877-303-7908 for domestic callers and 1-678-373-0875 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. To access a replay of the call please dial 1-855-859-2056 domestic callers and 1-404-537-3406 for international callers and use the conference ID number: 92632034. The archived version of the webcast and conference call will be available for 30 days on the Investor Relations section of the Company’s Web site at http://www.pharmacyclics.com.

About ibrutinib

B-cells are the immune cells in the body that are responsible for producing antibodies to fight infections and provide long term immunity. Ibrutinib is a B-cell receptor pathway inhibitor that interferes with the proteins involved in signaling and it effectively blocks signals that tell B-cells to grow and divide, uncontrollably. This therapy can help stop cancer progression while preserving normal, healthy cells. Ibrutinib is a first in its class, oral therapy and is a new agent that inhibits the B-cell receptor signaling complex that plays an important role in the survival of malignant B-cells. It is one of the first medicines to file for FDA approval via the new Breakthrough Therapy Designation pathway, bringing new hope to many suffering from CLL and other B-cell malignancies.

About Pharmacyclics

Pharmacyclics(®) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

We strive to be allies to all of our stakeholders – most importantly patients waging struggles against rare and incurable cancers – but also the physicians and family members who care for them, payers, our employees, our shareholders, and regulatory agencies working to bring life-changing medicines to patients.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to, generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words “anticipate”, “believe”, “estimate”, “expect”, “expectation”, “goal”, “should”, “would”, “project”, “plan”, “predict”, “intend”, “target” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management’s expectations or otherwise, except as may be required by law.


                               Pharmacyclics, Inc.

                      Condensed Consolidated Balance Sheets

                            (unaudited; in thousands)

                                          Sep. 30,             Dec. 31,

                                                  2013                 2012
                                                  ----                 ----

    Assets

    Cash, cash equivalents and
     marketable securities (1)                $560,100             $317,114

    Other current assets (2)                    64,310               29,378

           Total current assets                624,410              346,492
                                               -------              -------

    Property and equipment, net                 20,856                6,403

    Other assets                                 3,033                2,234

           Total assets                       $648,299             $355,129
                                                ======               ======

    Liabilities and Stockholders'
     Equity

    Deferred revenue -current
     portion                                    $7,411               $8,139

    Other current liabilities                   59,775               21,118
                                                ------               ------

           Total current liabilities            67,186               29,257

    Deferred revenue - non-current
     portion                                    52,054               62,562

    Deferred rent                                  707                  784
                                                   ---                  ---

           Total liabilities                   119,947               92,603

    Stockholders' equity                       528,352              262,526

           Total liabilities and
            stockholders' equity              $648,299             $355,129
                                                ======               ======

    (1)Marketable securities                   $11,667               $9,681
                                               =======               ======

    (2)As of September 30, 2013 and December 31, 2012, Other current
     assets includes $52.2 million and $26.6 million, respectively,
     due to the Company from Janssen under the collaboration and
     license agreement related to cost sharing and Excess Amounts.


                                                                              Pharmacyclics, Inc.

                                                                Condensed Consolidated Statements of Operations

                                                               (unaudited; in thousands, except per share data)

                                           Three Months Ended                  Nine Months Ended
                                           ------------------                  -----------------

                                                Sep. 30,                           Sep. 30,                     Sep. 30,           Sep. 30,

                                                               2013                               2012                       2013               2012
                                                               ----                               ----                       ----               ----

    Revenue:

      License and
       milestone
       revenue                                              $75,000                           $100,000                   $125,000           $100,000

      Collaboration
       services
       revenue                                                4,088                              2,695                     11,618              6,745

         Total revenue                                       79,088                            102,695                    136,618            106,745
                                                             ------                            -------                    -------            -------

    Operating expenses*:

      Research and
       Development                                           45,066                             19,072                    126,150             50,285

      Less: Excess
       amounts
       related to
       Research and
       Development                                          (34,146)                                 -                    (51,523)                 -

         Research and
          Development,
          net                                                10,920                             19,072                     74,627             50,285
                                                             ------                             ------                     ------             ------

      General and
       Administrative                                        26,120                              4,868                     63,882             13,149

      Less: Excess
       amounts
       related to
       General and
       Administrative                                       (11,378)                                 -                    (14,384)                 -

         General and
          Administrative,
          net                                                14,742                              4,868                     49,498             13,149
                                                             ------                              -----                     ------             ------

         Total operating
          expenses                                           25,662                             23,940                    124,125             63,434
                                                             ------                             ------                    -------             ------

    Income from
     operations                                              53,426                             78,755                     12,493             43,311

    Interest and
     other income,
     net                                                        148                                 52                        204                155
                                                                ---                                ---                        ---                ---

    Income before
     income taxes                                            53,574                             78,807                     12,697             43,466

    Income tax
     provision
     (benefit)                                               11,241                              3,201                      9,924             (2,411)

    Net income                                              $42,333                            $75,606                     $2,773            $45,877
                                                            =======                            =======                     ======            =======

    Net income per share:

        Basic                                                 $0.58                              $1.09                      $0.04              $0.66
                                                              =====                              =====                      =====              =====

        Diluted                                               $0.55                              $1.02                      $0.04              $0.62
                                                              =====                              =====                      =====              =====

    Weighted average shares used to compute

    net income per share:

        Basic                                                73,316                             69,512                     72,409             69,149
                                                             ======                             ======                     ======             ======

        Diluted                                              77,659                             74,456                     76,684             73,840
                                                             ======                             ======                     ======             ======

    * Includes share-based compensation as
     follows:

    Research and
     development                                             $5,287                             $2,590                    $20,227             $6,298

    General and
     administrative                                           4,849                                576                     20,348              2,201

                                                            $10,136                             $3,166                    $40,575             $8,499
                                                            =======                             ======                    =======             ======


                        Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)

                                (unaudited; in thousands, except per share data)

                              Three Months             Nine Months
                                  Ended                   Ended
                             -------------            ------------

                                Sep. 30,                Sep. 30,                Sep. 30,      Sep. 30,

                                         2013                    2012                    2013          2012
                                         ----                    ----                    ----          ----

    GAAP net
     income                           $42,333                 $75,606                  $2,773       $45,877

    Adjustments:

        Research and
         Development
         share-based
         compensation
         (2)                            5,287                   2,590                  20,227         6,298

        General and
         Administrative
         share-based
         compensation
         (2)                            4,849                     576                  20,348         2,201

                                       10,136                   3,166                  40,575         8,499
                                       ------                   -----                  ------         -----

    Non-GAAP net
     income                           $52,469                 $78,772                 $43,348       $54,376
                                      =======                 =======                 =======       =======

    GAAP net
     income per
     share -
     basic                              $0.58                   $1.09                   $0.04         $0.66

        Share-based
         compensation
         expense                         0.14                    0.04                    0.56          0.13

    Non-GAAP net
     income per
     share -
     basic                              $0.72                   $1.13                   $0.60         $0.79
                                        =====                   =====                   =====         =====

    GAAP net
     income per
     share -
     diluted                            $0.55                   $1.02                   $0.04         $0.62

        Share-based
         compensation
         expense                         0.13                    0.04                    0.53          0.12

    Non-GAAP net
     income per
     share -
     diluted                            $0.68                   $1.06                   $0.57         $0.74
                                        =====                   =====                   =====         =====


    (1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance with GAAP.

    (2) All stock-based compensation was excluded for the non-GAAP analysis.

SOURCE Pharmacyclics, Inc.


Source: PR Newswire